` BIOA B (BioArctic AB) vs OMX Stockholm 30 Comparison - Alpha Spread

BIOA B
vs
OMX Stockholm 30

Over the past 12 months, BIOA B has outperformed OMX Stockholm 30, delivering a return of -5% compared to the OMX Stockholm 30's 5% drop.

Stocks Performance
BIOA B vs OMX Stockholm 30

Loading
BIOA B
OMX Stockholm 30
Add Stock

Performance Gap
BIOA B vs OMX Stockholm 30

Loading
BIOA B
OMX Stockholm 30
Difference

Performance By Year
BIOA B vs OMX Stockholm 30

Loading
BIOA B
OMX Stockholm 30
Add Stock

Competitors Performance
BioArctic AB vs Peers

OMX Stockholm 30
BIOA B
ABBV
AMGN
GILD
VRTX
Add Stock

BioArctic AB
Glance View

Market Cap
16.7B SEK
Industry
Biotechnology

In the heart of Sweden, BioArctic AB carves its niche as a pioneering biopharmaceutical company with a resolute focus on neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Founded in 2003 by the innovative minds of Professor Lars Lannfelt and Dr. Pär Gellerfors, the company draws on cutting-edge science to develop novel treatments that target the underlying causes of these debilitating conditions. BioArctic’s scientific journey is rooted in its strategic use of monoclonal antibodies to halt or reverse the progression of neurological diseases. By zeroing in on the amyloid beta proteins and alpha-synuclein aggregates that play significant roles in Alzheimer’s and Parkinson’s diseases, respectively, BioArctic aims to provide therapies that go beyond mere symptom management to address the fundamental disease processes. At the core of BioArctic’s financial engine lies its collaborative business model, where strategic partnerships with pharmaceutical giants like Eisai and AbbVie are pivotal. These alliances not only bolster BioArctic’s research capabilities but also generate substantial revenue through milestone payments and royalties. Such collaborations allow BioArctic to leverage the vast distribution networks and financial muscle of its partners, facilitating the global commercialization of its therapies once they achieve regulatory approval. As the company continues to advance its pipeline through rigorous clinical trials, its combination of scientific rigor and strategic partnerships positions it as a formidable player in the quest to unravel and treat complex neurodegenerative diseases. Through its relentless innovation and well-crafted alliances, BioArctic stands at the forefront of transforming medical treatment for millions worldwide.

BIOA B Intrinsic Value
159.21 SEK
Overvaluation 16%
Intrinsic Value
Price
Back to Top